GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intravenous Infusions Ltd (XGHA:IIL) » Definitions » Asset Turnover

Intravenous Infusions (XGHA:IIL) Asset Turnover : 0.00 (As of . 20)


View and export this data going back to 2015. Start your Free Trial

What is Intravenous Infusions Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Intravenous Infusions's Revenue for the six months ended in . 20 was GHS Mil. Intravenous Infusions's Total Assets for the quarter that ended in . 20 was GHS Mil. Therefore, Intravenous Infusions's Asset Turnover for the quarter that ended in . 20 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Intravenous Infusions's annualized ROE % for the quarter that ended in . 20 was %. It is also linked to ROA % through Du Pont Formula. Intravenous Infusions's annualized ROA % for the quarter that ended in . 20 was %.


Intravenous Infusions Asset Turnover Historical Data

The historical data trend for Intravenous Infusions's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intravenous Infusions Asset Turnover Chart

Intravenous Infusions Annual Data
Trend
Asset Turnover

Intravenous Infusions Semi-Annual Data
Asset Turnover

Competitive Comparison of Intravenous Infusions's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Intravenous Infusions's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intravenous Infusions's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intravenous Infusions's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Intravenous Infusions's Asset Turnover falls into.



Intravenous Infusions Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Intravenous Infusions's Asset Turnover for the fiscal year that ended in . 20 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: . 20 )/( (Total Assets (A: . 20 )+Total Assets (A: . 20 ))/ count )
=/( (+)/ )
=/
=

Intravenous Infusions's Asset Turnover for the quarter that ended in . 20 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: . 20 )/( (Total Assets (Q: . 20 )+Total Assets (Q: . 20 ))/ count )
=/( (+)/ )
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Intravenous Infusions  (XGHA:IIL) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Intravenous Infusions's annulized ROE % for the quarter that ended in . 20 is

ROE %**(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=( / )*( / )*(/ )
=Net Margin %*Asset Turnover*Equity Multiplier
= %**
=ROA %*Equity Multiplier
= %*
= %

Note: The Net Income data used here is two times the semi-annual (. 20) net income data. The Revenue data used here is two times the semi-annual (. 20) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Intravenous Infusions's annulized ROA % for the quarter that ended in . 20 is

Note: The Net Income data used here is two times the semi-annual (. 20) net income data. The Revenue data used here is two times the semi-annual (. 20) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Intravenous Infusions Asset Turnover Related Terms

Thank you for viewing the detailed overview of Intravenous Infusions's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Intravenous Infusions (XGHA:IIL) Business Description

Traded in Other Exchanges
N/A
Address
Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.